

Poster session

N=134



Perceptions of ... after a false alarm


Pia Kirkegaard, MA, PhD¹; Adrian Edwards, MD, PhD^{1,2}; B.
¹Department of Public Health Programmes, Randers Region
²Division of Population Medicine, Cardiff University, Cardiff,
³Department of Clinical Medicine, Aarhus University, Aarhus

Background

- Colorectal cancer screening can reduce colorectal cancer incidence and mortality
- The Danish colorectal cancer screening program is a home-based fecal immunochemical testing (FIT) program
- Participation rate: 61%. Positive FIT rate: 7%. Colonoscopy attendance: 90%
- Colorectal cancer diagnosis: 6%
- "False alarm" for colorectal cancer: no abnormal FIT result; polyps/adenomas: 55%
- No long-term negative psychological impact on screening participants
- Coping before follow-up colonoscopy?
- Attitudes to screening after a "false alarm" for colorectal cancer?

Aim

- to explore how participants in a colorectal cancer screening program perceive and manage a positive screening result, followed by a non-cancer colonoscopy result.



Methods

- Recruitment: screening administration call center
- Maximum variation sampling: age, sex, marital status
- Interviews before and after colonoscopy: 45-90 minutes
- Transcripts, field notes: thematic analysis, ethnography

Conclusion

- Coping during waiting period included
- Patient involvement during colonoscopy
- A "false alarm" for cancer may not

Anton Pottegård
Timothy L. Lash
Deidre Cronin - Fe
Thomas P. Ahern
Per Damkier

USE OF ANTIPSYCHOTICS AND RISK OF BREAST CANCER



ANTON POTTEGÅRD
apotteg@health.sdu.dk
Clinical Pharmacology & Pharmacy
Department of Public Health
University of Southern Denmark
Denmark

Some antipsychotics increases prolactin levels, which might increase the risk of breast cancer. In a Danish case-control study based on 60,360 female breast cancer patients, long-term use ($\geq 10,000$ mg olanzapine equivalents) was associated with breast cancer, with an adjusted OR of 1.13 (95% CI, 1.06, 1.32) and a weak dose-response pattern. Associations were similar for first- and second-generation antipsychotics (ORs 1.17 and 1.11), but also for non-prolactin inducing antipsychotics (OR 1.17). Upon stratification, positive associations were seen for estrogen receptor positive but not for estrogen receptor negative cancers (OR 1.29 vs 0.92). Overall, our results do not suggest a clinically important association between antipsychotic use and risk of breast cancer.

www.anton.pottegaard.dk/anti-psych-breast.pdf

British Journal of Clinical Pharmacology
ORIGINAL ARTICLE
Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study

Correspondence: Associate Professor Anton Pottegård, Clinical Pharmacology and Pharmacy, University of Southern Denmark, Hvidovrevej 14, 2-100, 5000 Odense C, Denmark. Email: anton.pottegaard@sdu.dk
Received 23 February 2018; accepted 25 May 2018; accepted online 20 June 2018
© Pottegård et al. Timothy L. Lash^{1,2}, Deidre Cronin-Feest³, Thomas P. Ahern⁴ and Per Damkier^{1,2}
¹Department of Clinical Pharmacology and Pharmacy, ²Department of Public Health, University of Southern Denmark, Odense, Denmark, ³Department of Epidemiology, Boston School of Public Health, Boston, MA, USA, ⁴Department of Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark, and ⁵Department of Clinical Health, University of Southern Denmark, Odense, Denmark

Pre-treatment weight loss

increases risk of death prior to 4th cycle of anti-neoplastic treatment in patients with inoperable non-small cell lung cancer (LUCANU-1)

Tobberup R*, Jensen NA**, Rasmussen HH*, Holst M*, Carus A**
*Department of Gastroenterology, Aalborg University Hospital
** Department of Oncology, Aalborg University Hospital

Aim

To assess the risk of death before 4th cycle of systemic treatment in relation to pre-treatment weight loss in patients with newly diagnosed non-small cell lung cancer (NSCLC).

Method

Study group

- 60 newly diagnosed patients with inoperable NSCLC
- Naïve to systemic anti-neoplastic treatment (chemotherapy or immune-checkpoint inhibitor)
- Curative intended treatment (n=13), palliative chemotherapy (n=34), palliative immunotherapy (n=13)

Study design


- Prospective observation from 1st to 4th cycle of treatment
- Pre-treatment weight loss previous month was self-reported
- Patients' risk of death was calculated as odds ratio and chi-square test

Results

- 37 patients reported loss of body weight prior to commencing treatment (range 0.4-14.7 kg)
- 22 patients reported weight loss greater than or equal to ≥ 2.5 %
- 9 patients died, 8 of which had lost ≥ 2.5 % body weight prior to commencing treatment
- Patients with pre-treatment weight loss ≥ 2.5 % were 4.57 times more likely to die prior to 4th cycle ($\chi^2=20.7$, $p<0.001$).



Eight of nine patients who died prior to 1st status CT scan had lost ≥ 2.5 % body weight previous month prior to treatment start



Conclusions

NSCLC patients undergoing systemic anti-neoplastic treatment with ≥ 2.5 % pre-treatment weight loss are more likely to die prior to 4th cycle than patients without pre-treatment weight loss.

The pattern of recurrence in Danish stage I lung cancer patients in relation to the follow-up program. Are we failing to identify patients with cerebral recurrence?

N.L. Christensen, S.O. Dalton, A. Mellemegaard, J. Christensen, A.M. Kejs, T. Riis Rasmussen

Background

Evidence supporting any of the current follow-up guidelines is weak. Denmark has a high intensity follow-up regimen with a CT of the chest and upper abdomen every three months for the first two years (early phase). Then every six months for an additional three years (late phase). No available follow-up data from the nationwide registries.

Aims

In a population-based nested case/control study, we aimed to characterize patients with recurrence diagnosed outside the Danish follow-up program in terms of Site of recurrence, Follow-up department, Phase of Follow-up

Results

	Symptomatic group (n=36)	FU group (n=197)	P-value
	%	%	
Age at diagnosis (range) ^a	72.2 (50-87)	71.3 (47-90)	0.58
Gender (female/male)	50/50	43/57	0.41
Primary treatment			
Surgery	69	66	0.69
SBRT	25	32	0.40
Other	6	2	0.22
Follow-up Department			
Oncology	72	68	0.62
Pulmonology	19	26	0.38
Other	8	6	0.52
Diagnostic tests (FU)			
Cerebral MRI or CT	61	6.5	<0.00
FDG PET	28	72	<0.00
	25	33	0.34
		30	<0.01
		30	0.01

The Danish follow-up and...

- Local recurrence 👍
- Nodal recurrence 👍
- CNS recurrence 👎
- Length of interval 🙌

Cerebral imaging in the follow-up?

